RxDoctor Payments DataLook up a doctor →

Nikki Inamine, MD

Internal Medicine · Honolulu, HINPI 1780848556

Payments from drug & device makers

$16,640in general payments, 2019–2025

Across 942 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$3K
  • AstraZeneca$2K
  • Novo Nordisk$2K
  • Boehringer Ingelheim$1K
  • Pfizer$1K
  • Kowa Pharmaceuticals America, Inc.$1K
  • plus $6K from 21 others

What the payments were for

  • Food & beverage$16,621100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,640 in reported general payments places this provider in the 90th percentile of 655 internal medicine providers in Hawaii.

See all internal medicine providers in Hawaii

Medicare billing

Part B allowed, 2024
$14,167
Medicare patients
77
Services billed
210

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Atorvastatin Calcium73$2,473
Rosuvastatin Calcium30$1,798
Amlodipine Besylate24$628
Amlodipine Besylate-BenazeprilAmlodipine Besylate/Benazepril11$543
Losartan Potassium22$497
Metoprolol Succinate19$382
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav24$360
Simvastatin15$346
Albuterol Sulfate HfaAlbuterol Sulfate20$323
Pantoprazole Sodium11$242
Allopurinol15$234
Levothyroxine Sodium24$221
Metformin Hcl ErMetformin Hcl18$189
Azithromycin20$172
Prednisone13$14

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPaxlovid$1,431$019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 655 internal medicine providers in Hawaii.

Other internal medicine in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →